The global Ibritumomab Tiuxetan market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
It is the world"s first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin"s lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.
The U.S. market is estimated at $ million in 2024, while China is to reach $ million.
0.05 segment will reach $ million by 2032, with a % CAGR in next six years.
The global key players of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
We have surveyed the Ibritumomab Tiuxetan companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Ibritumomab Tiuxetan, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ibritumomab Tiuxetan. This report contains market size and forecasts of Ibritumomab Tiuxetan in global, including the following market information:
Global Ibritumomab Tiuxetan market revenue, 2020-2025, 2026-2032, ($ millions)
Global top five Ibritumomab Tiuxetan companies in 2024 (%)
Total Market by Segment:
Global Ibritumomab Tiuxetan market, by Type, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by Type, 2024 (%)
0.05
0.25
Global Ibritumomab Tiuxetan market, by Application, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by Application, 2024 (%)
Follicular Non-hodgkin Lymphoma
Metastatic B-cell Non-hodgkin Lymphoma
Global Ibritumomab Tiuxetan market, by region and country, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ibritumomab Tiuxetan revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Ibritumomab Tiuxetan revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
CASI Pharmaceuticals
Biogen
Bayer
Spectrum
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ibritumomab Tiuxetan, market overview.
Chapter 2: Global Ibritumomab Tiuxetan market size in revenue.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ibritumomab Tiuxetan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Ibritumomab Tiuxetan Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Ibritumomab Tiuxetan Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ibritumomab Tiuxetan Overall Market Size
2.1 Global Ibritumomab Tiuxetan Market Size: 2024 VS 2032
2.2 Global Ibritumomab Tiuxetan Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Ibritumomab Tiuxetan Players in Global Market
3.2 Top Global Ibritumomab Tiuxetan Companies Ranked by Revenue
3.3 Global Ibritumomab Tiuxetan Revenue by Companies
3.4 Top 3 and Top 5 Ibritumomab Tiuxetan Companies in Global Market, by Revenue in 2024
3.5 Global Companies Ibritumomab Tiuxetan Product Type
3.6 Tier 1, Tier 2, and Tier 3 Ibritumomab Tiuxetan Players in Global Market
3.6.1 List of Global Tier 1 Ibritumomab Tiuxetan Companies
3.6.2 List of Global Tier 2 and Tier 3 Ibritumomab Tiuxetan Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Ibritumomab Tiuxetan Market Size Markets, 2024 & 2032
4.1.2 0.05
4.1.3 0.25
4.2 Segmentation by Type - Global Ibritumomab Tiuxetan Revenue & Forecasts
4.2.1 Segmentation by Type - Global Ibritumomab Tiuxetan Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Ibritumomab Tiuxetan Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Ibritumomab Tiuxetan Market Size, 2024 & 2032
5.1.2 Follicular Non-hodgkin Lymphoma
5.1.3 Metastatic B-cell Non-hodgkin Lymphoma
5.2 Segmentation by Application - Global Ibritumomab Tiuxetan Revenue & Forecasts
5.2.1 Segmentation by Application - Global Ibritumomab Tiuxetan Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Ibritumomab Tiuxetan Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Ibritumomab Tiuxetan Market Size, 2024 & 2032
6.2 By Region - Global Ibritumomab Tiuxetan Revenue & Forecasts
6.2.1 By Region - Global Ibritumomab Tiuxetan Revenue, 2020-2025
6.2.2 By Region - Global Ibritumomab Tiuxetan Revenue, 2026-2032
6.2.3 By Region - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Ibritumomab Tiuxetan Revenue, 2020-2032
6.3.2 United States Ibritumomab Tiuxetan Market Size, 2020-2032
6.3.3 Canada Ibritumomab Tiuxetan Market Size, 2020-2032
6.3.4 Mexico Ibritumomab Tiuxetan Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Ibritumomab Tiuxetan Revenue, 2020-2032
6.4.2 Germany Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.3 France Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.4 U.K. Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.5 Italy Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.6 Russia Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.7 Nordic Countries Ibritumomab Tiuxetan Market Size, 2020-2032
6.4.8 Benelux Ibritumomab Tiuxetan Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Ibritumomab Tiuxetan Revenue, 2020-2032
6.5.2 China Ibritumomab Tiuxetan Market Size, 2020-2032
6.5.3 Japan Ibritumomab Tiuxetan Market Size, 2020-2032
6.5.4 South Korea Ibritumomab Tiuxetan Market Size, 2020-2032
6.5.5 Southeast Asia Ibritumomab Tiuxetan Market Size, 2020-2032
6.5.6 India Ibritumomab Tiuxetan Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Ibritumomab Tiuxetan Revenue, 2020-2032
6.6.2 Brazil Ibritumomab Tiuxetan Market Size, 2020-2032
6.6.3 Argentina Ibritumomab Tiuxetan Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Ibritumomab Tiuxetan Revenue, 2020-2032
6.7.2 Turkey Ibritumomab Tiuxetan Market Size, 2020-2032
6.7.3 Israel Ibritumomab Tiuxetan Market Size, 2020-2032
6.7.4 Saudi Arabia Ibritumomab Tiuxetan Market Size, 2020-2032
6.7.5 UAE Ibritumomab Tiuxetan Market Size, 2020-2032
7 Companies Profiles
7.1 CASI Pharmaceuticals
7.1.1 CASI Pharmaceuticals Corporate Summary
7.1.2 CASI Pharmaceuticals Business Overview
7.1.3 CASI Pharmaceuticals Ibritumomab Tiuxetan Major Product Offerings
7.1.4 CASI Pharmaceuticals Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.1.5 CASI Pharmaceuticals Key News & Latest Developments
7.2 Biogen
7.2.1 Biogen Corporate Summary
7.2.2 Biogen Business Overview
7.2.3 Biogen Ibritumomab Tiuxetan Major Product Offerings
7.2.4 Biogen Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.2.5 Biogen Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Corporate Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Ibritumomab Tiuxetan Major Product Offerings
7.3.4 Bayer Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.3.5 Bayer Key News & Latest Developments
7.4 Spectrum
7.4.1 Spectrum Corporate Summary
7.4.2 Spectrum Business Overview
7.4.3 Spectrum Ibritumomab Tiuxetan Major Product Offerings
7.4.4 Spectrum Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.4.5 Spectrum Key News & Latest Developments
7.5 CSL Behring
7.5.1 CSL Behring Corporate Summary
7.5.2 CSL Behring Business Overview
7.5.3 CSL Behring Ibritumomab Tiuxetan Major Product Offerings
7.5.4 CSL Behring Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.5.5 CSL Behring Key News & Latest Developments
7.6 Grifols
7.6.1 Grifols Corporate Summary
7.6.2 Grifols Business Overview
7.6.3 Grifols Ibritumomab Tiuxetan Major Product Offerings
7.6.4 Grifols Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.6.5 Grifols Key News & Latest Developments
7.7 Baxalta
7.7.1 Baxalta Corporate Summary
7.7.2 Baxalta Business Overview
7.7.3 Baxalta Ibritumomab Tiuxetan Major Product Offerings
7.7.4 Baxalta Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.7.5 Baxalta Key News & Latest Developments
7.8 Octapharma
7.8.1 Octapharma Corporate Summary
7.8.2 Octapharma Business Overview
7.8.3 Octapharma Ibritumomab Tiuxetan Major Product Offerings
7.8.4 Octapharma Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.8.5 Octapharma Key News & Latest Developments
7.9 Kedrion
7.9.1 Kedrion Corporate Summary
7.9.2 Kedrion Business Overview
7.9.3 Kedrion Ibritumomab Tiuxetan Major Product Offerings
7.9.4 Kedrion Ibritumomab Tiuxetan Revenue in Global Market (2020-2025)
7.9.5 Kedrion Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Ibritumomab Tiuxetan Market Opportunities & Trends in Global Market
Table 2. Ibritumomab Tiuxetan Market Drivers in Global Market
Table 3. Ibritumomab Tiuxetan Market Restraints in Global Market
Table 4. Key Players of Ibritumomab Tiuxetan in Global Market
Table 5. Top Ibritumomab Tiuxetan Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Ibritumomab Tiuxetan Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Ibritumomab Tiuxetan Revenue Share by Companies, 2020-2025
Table 8. Global Companies Ibritumomab Tiuxetan Product Type
Table 9. List of Global Tier 1 Ibritumomab Tiuxetan Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ibritumomab Tiuxetan Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Ibritumomab Tiuxetan Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Ibritumomab Tiuxetan Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Ibritumomab Tiuxetan Revenue, (US$, Mn), 2026-2032
Table 30. CASI Pharmaceuticals Corporate Summary
Table 31. CASI Pharmaceuticals Ibritumomab Tiuxetan Product Offerings
Table 32. CASI Pharmaceuticals Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 33. CASI Pharmaceuticals Key News & Latest Developments
Table 34. Biogen Corporate Summary
Table 35. Biogen Ibritumomab Tiuxetan Product Offerings
Table 36. Biogen Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 37. Biogen Key News & Latest Developments
Table 38. Bayer Corporate Summary
Table 39. Bayer Ibritumomab Tiuxetan Product Offerings
Table 40. Bayer Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 41. Bayer Key News & Latest Developments
Table 42. Spectrum Corporate Summary
Table 43. Spectrum Ibritumomab Tiuxetan Product Offerings
Table 44. Spectrum Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 45. Spectrum Key News & Latest Developments
Table 46. CSL Behring Corporate Summary
Table 47. CSL Behring Ibritumomab Tiuxetan Product Offerings
Table 48. CSL Behring Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 49. CSL Behring Key News & Latest Developments
Table 50. Grifols Corporate Summary
Table 51. Grifols Ibritumomab Tiuxetan Product Offerings
Table 52. Grifols Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 53. Grifols Key News & Latest Developments
Table 54. Baxalta Corporate Summary
Table 55. Baxalta Ibritumomab Tiuxetan Product Offerings
Table 56. Baxalta Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 57. Baxalta Key News & Latest Developments
Table 58. Octapharma Corporate Summary
Table 59. Octapharma Ibritumomab Tiuxetan Product Offerings
Table 60. Octapharma Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 61. Octapharma Key News & Latest Developments
Table 62. Kedrion Corporate Summary
Table 63. Kedrion Ibritumomab Tiuxetan Product Offerings
Table 64. Kedrion Ibritumomab Tiuxetan Revenue (US$, Mn) & (2020-2025)
Table 65. Kedrion Key News & Latest Developments
List of Figures
Figure 1. Ibritumomab Tiuxetan Product Picture
Figure 2. Ibritumomab Tiuxetan Segment by Type in 2024
Figure 3. Ibritumomab Tiuxetan Segment by Application in 2024
Figure 4. Global Ibritumomab Tiuxetan Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Ibritumomab Tiuxetan Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Ibritumomab Tiuxetan Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Ibritumomab Tiuxetan Revenue in 2024
Figure 9. Segmentation by Type � Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Ibritumomab Tiuxetan Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 13. By Region - Global Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 14. By Country - North America Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 15. United States Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 19. Germany Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 20. France Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 27. China Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 31. India Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 33. Brazil Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Ibritumomab Tiuxetan Revenue Market Share, 2020-2032
Figure 36. Turkey Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Ibritumomab Tiuxetan Revenue, (US$, Mn), 2020-2032
Figure 40. CASI Pharmaceuticals Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Biogen Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. Bayer Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Spectrum Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. CSL Behring Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Grifols Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Baxalta Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. Octapharma Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Kedrion Ibritumomab Tiuxetan Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
